The Value of Treatment (VOT) research project, initiated and coordinated by EBC, aims to identify treatment gaps and causing factors along the care pathway and propose solutions to address them; assess health gains and socio-economic impacts resulting from best practice healthcare interventions, in comparison with current care or no treatment. Furthermore, its objective is to converge evidence to policy.

In the framework of this project, new case studies within a second round of the VOT research (VOT 2) have been developed. Studies on new therapeutic areas focusing on:

  • rare neurological diseases (Ataxia, Dystonia and Phenylketonuria)
  • mental disorders (Anorexia Nervosa, Autism Spectrum Disorder, Major Depressive Disorder)

were launched respectively in 2018 and in 2019.

As a follow-up to the 6th October 2020 VOT 2 consensus meeting and as part of the consolidation of the economic analysis and the proposed approach for more homogeneity in treatment and organization of care for the pathologies under study, two working sessions were organized on 11 December 2020.

For the Value of Treatment 2 – mental health disorders groups (Anorexia Nervosa, Autism Spectrum Disorder, Major Depressive Disorder), aim of this informative session was to interact with Judit Simon, Professor of Health Economics Medical University of Vienna, Austria on potential options for harmonization across case studies using the EU Horizon 2020 Pecunia project tools as an example.

For the Value of Treatment 2-rare diseases groups (Ataxias, Dystonia, Phenylketonuria), aim of the session was to discuss the “optimized” care pathway approach method proposed by Giuseppe Turchetti, Professor of Health Economics, Scuola Superiore Sant’ Anna – Pisa, Italy and to complement the WGs ongoing extremely valuable research (surveys and statistical analysis).

For more information on the Value of Treatment project, see here.